MRI Before Prostate Biopsy Gains Rapid Adoption in U.S. Hospitals
A sharp rise in pre-biopsy MRI use reflects growing evidence that targeted imaging finds more clinically significant cancers.
Prostate MRI before biopsy is becoming standard practice at U.S. hospitals, with usage climbing sharply in recent years. The shift follows a body of evidence from multiple randomized trials demonstrating that imaging the prostate first and then targeting suspicious lesions improves detection of the aggressive cancers that matter most.
Guidelines have been updated to reflect this advance, and hospitals are responding by integrating MRI into their diagnostic workflows. The trend marks a real improvement in prostate cancer diagnosis, moving away from systematic sampling toward a more precise, image-guided approach.
While the source notes the increase is sharp, it does not provide specific numbers or compare adoption rates across hospital types. The overall direction is clear: pre-biopsy MRI is now a key tool in catching clinically significant disease earlier and more reliably.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.